This inventor holds 1 USPTO granted patent. Top assignees: Merck Sante, National Institute of Health and Medical Research. Active years: 2012.
Company Filing History:
1 out of 5 
1 out of 1,853 
Years Active: 2012
Title: Clarisse Paget: Innovator in Diabetic Retinopathy Treatment
Introduction
Clarisse Paget is a notable inventor based in Lyon, France. She has made significant contributions to the field of medical research, particularly in the treatment of diabetic retinopathy. Her innovative approach focuses on the use of pericyte apoptosis inhibitors to prevent and treat this condition.
Latest Patents
Clarisse Paget holds a patent for her groundbreaking work titled "Methods of treating diabetic retinopathy with pericyte apoptosis inhibitors." This patent describes a method of preventing or treating diabetic retinopathy by administering a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Additionally, the patent includes a pharmaceutical composition that treats and/or prevents diabetic retinopathy, comprising a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier. She has 1 patent to her name.
Career Highlights
Throughout her career, Clarisse has worked with prominent organizations such as Merck Santé and the National Institute of Health and Medical Research. Her experience in these institutions has allowed her to develop her expertise in medical research and innovation.
Collaborations
Clarisse has collaborated with esteemed colleagues, including Marc Lecomte and Nicolas Wiernsperger. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Clarisse Paget is a pioneering inventor whose work in diabetic retinopathy treatment showcases her dedication to medical innovation. Her contributions are vital in the ongoing fight against this condition, and her patent reflects her commitment to improving patient outcomes.